CT-XEROX
18.11.2020 21:07:11 CET | Business Wire | Press release
Xerox (NYSE: XRX) announced a suite of production print innovations including new presses, technology enhancements for existing printers as well as artificial intelligence and automation features that aid speed and productivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118006025/en/
At a virtual event attended by partners and clients around the world, Xerox unveiled the following innovations:
- A Color Accelerator module for Baltoro, expanding inkjet applications and adding ink-saving automation
- Addition of fluorescent pink to the Iridesse Production Press, enhancing its metallics, white and clear color palette
- Three new printers capable of higher volumes, more media and extended color options in the VersaLink and Versant family
- Two Xerox Nuvera print speed upgrades that best competition
- AI-enabled media manager software that enables high-quality images with minimal set-up and staff time
- Automated workflow updates to seamlessly print embellishments with FreeFlow Core 6.0
As the leader in the production color market, Xerox is committed to helping customers expand their business, enhance productivity with new technology and protect their existing investments with new tools and features.
Digital print enhancements increase profitability, delivering higher margins and allowing print customers to expand into new areas. According to Keypoint Intelligence, digital print enhancement is expected to generate $25 billion a year and can increase a printers’ profit by 50 to 400 percent. By making it easier, customizable and faster to produce these pages, Xerox technology provides multiple entry options for customers to expand their business and increase profit.
“Print enhancement is the fastest-growing segment in print and Xerox offers the broadest set of solutions to help clients expand their business here,” said Tracey Koziol, senior vice president of Global Offerings, Xerox. “The new technology and features we are launching expand the capabilities and profit potential of existing devices while introducing new presses that respond to demand for higher volume and extended media and color palettes. There’s a reason Xerox remains top in the production print market.”
Xerox Color Accelerator for Baltoro
The Xerox Baltoro™ High Fusion Inkjet Press platform, No. 1 in the B3 cut-sheet inkjet market, now has a field-upgradable module that expands its range. The Xerox Color Accelerator for Xerox Baltoro HF Inkjet Press
enables increased print quality, expanded media options and automation to make inkjet printing viable for lucrative applications such as direct mail, postcards and catalogs. With intelligent automation, Baltoro uses 50% less ink than competitor presses to purge inkjet heads, increasing uptime and productivity while delivering consistent, reliable quality.
Introduced last year, Baltoro is redefining the inkjet market. At a fraction of the size, weight and power consumption of competitor presses, Baltoro offers a lower total cost of ownership (TCO) while being the only scalable, customizable platform in its class.
Fluorescent Pink for Iridesse
Xerox has the broadest color capability and Beyond CMYK offerings across any portfolio. No one offers the range of colors, embellishments, mixed metallics, extended gamut, media options and single-pass digital enhancement technology as Xerox.
The Xerox Iridesse® Production Press is adding fluorescent pink specialty dry ink option to its existing Beyond CMYK palette of gold, silver, white and clear. These embellishments allow print providers to differentiate and offer their clients eye-popping designs and enhancements.
New VersaLink Graphic Arts Printer
The newest addition to our VersaLink family is the Xerox VersaLink®
C8000W
, the most affordable entry point into the embellishment market. Using white toner as a base on dark and colored stocks, its cyan, magenta and yellow toners make images pop for applications such as menus, envelopes, window clings, decals and labels. A small footprint device, the C8000W offers clarity and quality that stands out over the typical four-color print.
Two New Versants
Xerox is expanding its Versant family of presses with two new machines that support wider media options and add automation features that reduce staffing needs and set-up time.
The Xerox Versant® 280 Press , a mid-production press, provides added value with thicker stock media options (400 GSM) for applications such as business cards. With the All Stocks at Rated Speed (ASRS) option, the Versant 280 is faster than any competitor in printing heavy stocks. Customers can print a million specialty colors using an Adaptive CMYK+ kit that leverages white, gold, silver, clear and fluorescents, unique to Xerox in this class of products.
The Xerox Versant 4100 Press , handles higher volumes and heavier production loads than the Versant 280, bringing more jobs in-house by reducing set-up time and printing on more media types than any competitor press. The 4100 also handles thicker paper stocks, up to 400 GSM. Automated stock management saves time and reduces human error.
Faster Xerox Nuveras
The Xerox Nuvera®
family is built for high production environments with our customers making more than 35 billion prints last year. The Xerox Nuvera 157 MX Production System
and Xerox Nuvera MX Perfecting Production System
monochrome production presses have upgraded the magnetic ink character recognition (MICR) print speeds to exceed any competitive press. MICR, the line of numbers that allows certain computers to read and process information, is key for processing bank, payroll and government checks with tested and trusted Xerox Nuvera security.
Technology-Driven Efficiencies
AI-enabled media manager software. PredictPrint
Media Manager Software is included with the new Versant 4100 and can be added to Iridesse. By using artificial intelligence, the software automatically identifies the media being used and provides the correct press settings. Users simply scan a barcode, place the paper in a tray, and use the set-up wizard to walk through optimizing the system for that application.
FreeFlow® Core 6.0 automates the process of preparing a file to print and now includes the application of Beyond CMYK enhancements. FreeFlow Core uses pre-built workflows to seamlessly apply embellishments such as gold, silver, white, clear and fluorescents without changing the source file.
“These new products and features represent the sweet spot of technology, where end-to-end solutions support our customers need to differentiate and expand their businesses in any economic environment,” said Marybeth Gilbert, vice president and general manager, Production Business, Xerox. “Our customers know they can count on Xerox innovation in response to their business needs.”
Availability:
- Xerox Color Accelerator for Xerox Baltoro HF Inkjet Press - Current Baltoro customers will be able to order Color Accelerator beginning in 2021. New Baltoro customers will be able to place orders for Color Accelerator starting December 15 with installs expected to begin in Q1 2021.
- The VersaLink C8000W is available immediately worldwide.
- The Xerox Nuvera 157 MX Production System and Xerox Nuvera 314 MX Perfecting Production System - order taking and availability December 1, 2020.
- The Xerox Versant 280 is available now based upon channel and geography.
- The Xerox Versant 4100 with PredictPrint Media Manager Software is available now based upon channel and geography.
- Iridesse pink specialty dry ink option and the PredictPrint Media Manager Software option are available for order taking December 1, 2020 and availability beginning March 1, 2021.
- The XLS Automatic Feeding Kit option for Iridesse is available immediately worldwide.
About Xerox
Xerox Holdings Corporation (NYSE: XRX) makes every day work better.
We are a workplace technology company building and integrating software and hardware for enterprises large and small. As customers seek to manage information across digital and physical platforms, Xerox delivers a seamless, secure and sustainable experience. Whether inventing the copier, Ethernet, the laser printer or more, Xerox has long defined the modern work experience. Learn how that innovation continues at xerox.com
.
Note: To receive RSS news feeds, visit https://www.news.xerox.com . For open commentary, industry perspectives and views, visit http://twitter.com/xerox , http://www.facebook.com/XeroxCorp , https://www.instagram.com/xerox/ , http://www.linkedin.com/company/xerox , http://www.youtube.com/XeroxCorp .
Xerox® , Baltoro™, FreeFlow® , Iridesse® , VersaLink® , Versant® and Xerox Nuvera® are trademarks of Xerox in the United States and/or other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118006025/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
